B12 Injection Side Effects: What Studies Report

Vitamin B12 injection, supplied as cyanocobalamin or hydroxocobalamin solution for intramuscular or subcutaneous administration, is a prescription medicine authorised by national regulators including the US Food and Drug Administration, and in several countries certain presentations are also available under pharmacy supervision. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning vitamin B12 injection, including whether it is appropriate in a given situation and what adverse effects might matter for a particular person. Nothing here is a dosing instruction, a recommendation or a safety verdict.

Adverse-event information for an old, widely used injectable vitamin comes from two uneven sources. The first is approved product labeling, which lists events observed in clinical use but frequently without numerical frequencies. The second is the clinical literature, where vitamin B12 injection appears across very different settings: haematology, neurology, pain medicine and oncology supportive care. Many of those publications were designed to measure efficacy or physiology rather than to characterise harms, so structured adverse-event tables are often absent.

What the verified records on this page cover

Hypersensitivity and allergic reactions: What Studies Report

Approved labeling for cyanocobalamin injection has long listed hypersensitivity reactions, including anaphylaxis and reports of death following parenteral administration, among events observed in clinical use. Labeling also notes that sensitivity to cobalamin can be assessed before administration in people with a suspected allergy history. These label entries are descriptive rather than quantified, so they do not provide an incidence rate, and they do not separate cyanocobalamin from hydroxocobalamin presentations.

The verified clinical records summarised on this page did not set out to measure allergic reaction rates. The case report of ultrasound-guided perineural vitamin B12 injection combined with pulsed radiofrequency of the C2 dorsal root ganglion described a single patient treated for C2 postherpetic neuralgia (PMID 42063934), and a single case cannot establish how often hypersensitivity occurs. Readers looking for allergy frequency data will not find it in that record.

Skin and injection-site reactions: What Studies Report

Labeling for cyanocobalamin injection lists transitory exanthema and itching among reported skin events, again without frequencies. Injection-site pain, redness and transient swelling are generic consequences of intramuscular or subcutaneous administration and are commonly recorded in injection trials of many drug classes rather than being unique to cobalamin.

Among the verified records, the randomised controlled trial of vitamin B12 injection combined with traditional Chinese medicine techniques in meralgia paresthetica used a randomised, controlled design in which local reactions would normally fall within the collected safety data (PMID 41601808). This page does not restate local-reaction counts from that trial because the citation set used here does not include extracted frequency tables; the trial record itself is the correct place to check what researchers logged.

Cardiovascular and fluid balance signals: What Studies Report

Cyanocobalamin injection labeling describes pulmonary oedema and congestive heart failure occurring early in treatment, together with peripheral vascular thrombosis, among events reported in clinical use. These entries are generally understood in relation to the rapid haematological response that can follow correction of severe deficiency, when potassium and fluid shifts occur. Labeling does not attach incidence figures to these events, and no randomised safety trial quantifying them appears in the verified record set for this page.

Haematological and electrolyte effects: What Studies Report

Labeling lists hypokalaemia and polycythaemia vera among reported events associated with cyanocobalamin injection, and notes that treatment of severe megaloblastic anaemia may unmask or worsen a potassium deficit as red cell production accelerates. Laboratory monitoring in that early phase is a clinical decision for a prescribing physician and is not addressed by the records cited here.

Diagnostic context matters for interpreting these entries. The study of the CobaSorb absorption test examined whether an absorption test could identify patients who did not require vitamin B12 injection therapy, which bears on who is exposed to injections in the first place (PMID 21623649). The study addressed test performance and patient selection rather than injection adverse events, so it contributes nothing to harm frequencies.

Gastrointestinal events: What Studies Report

Mild transient diarrhoea appears in cyanocobalamin injection labeling among reported events, without a frequency estimate. The clinical records summarised on this page do not isolate gastrointestinal effects attributable to the vitamin itself. In oncology supportive care, gastrointestinal symptoms are dominated by the chemotherapy regimen: the prospective study of shortened vitamin supplementation before cisplatin-pemetrexed therapy was conducted in non-small cell lung cancer patients receiving cytotoxic treatment (PMID 25260366), so symptoms recorded in that population reflect the whole regimen rather than vitamin B12 alone.

Neurological and pain-medicine settings: What Studies Report

Vitamin B12 injection has been studied as a local or perineural intervention in pain conditions, which introduces procedure-related risks distinct from systemic vitamin effects, including needle-related injury, bleeding and infection at the site. The case report of combined ultrasound-guided perineural vitamin B12 injection and pulsed radiofrequency of the C2 dorsal root ganglion described this combined procedural approach in one patient with C2 postherpetic neuralgia (PMID 42063934), and the randomised controlled trial in meralgia paresthetica combined vitamin B12 injection with traditional Chinese medicine techniques (PMID 41601808). In both designs, any adverse event is attributable to a combination of interventions rather than to the vitamin in isolation, which limits what can be inferred about cobalamin itself.

Oncology supportive-care settings: What Studies Report

Vitamin B12 injection is used as part of supplementation alongside pemetrexed-containing chemotherapy. The prospective study of a shortened vitamin supplementation schedule before cisplatin-pemetrexed therapy enrolled non-small cell lung cancer patients and examined that shortened schedule (PMID 25260366), while a separate clinical report examined vitamin support in lung adenocarcinoma patients treated with pemetrexed as second-line chemotherapy (PMID 26887521). Adverse events in those populations are reported against a background of cytotoxic therapy, meaning attribution to the vitamin component is not straightforward and the studies were not designed to isolate it.

Animal data: What Studies Report

Animal work on one-carbon metabolism sits at a different level of evidence. A 2024 study in heifers examined disrupted one-carbon metabolism and its negative effects on health and physiology (PMID 38770669). Species differences in cobalamin handling, dosing routes and physiology mean such findings describe animal biology and do not translate into human adverse-event rates.

Where structured adverse-event data are missing

• No randomised controlled trial in the verified set was designed primarily to quantify vitamin B12 injection harms by body system.
• Labeling entries for cyanocobalamin injection are largely unquantified, so incidence per thousand exposures cannot be derived from them.
• Case reports describe single patients, so the 2026 perineural injection report cannot generate rates (PMID 42063934).
• Oncology studies combine the vitamin with chemotherapy, which confounds attribution (PMID 26887521).
• Diagnostic studies such as the absorption-test work address patient selection rather than harms (PMID 21623649).

How to read adverse-event reporting in this literature

1. Check the design. Case reports, prospective cohorts and randomised trials carry different weight for harms, and the records cited here span all three.
2. Check the population. Oncology patients receiving cisplatin and pemetrexed differ substantially from otherwise healthy adults with deficiency (PMID 25260366).
3. Check co-interventions. When the vitamin was combined with radiofrequency or manual techniques, events cannot be assigned to one component (PMID 41601808).
4. Check whether frequencies were reported at all. Absence of a tabulated rate is not evidence that an event did not occur.

Questions that belong with a prescribing clinician

Decisions about whether vitamin B12 injection is indicated, which formulation is used, how often administration occurs, and what monitoring applies are matters for a licensed prescriber who can see the full clinical picture, including kidney function, potassium status, allergy history and concurrent medicines. Published absorption testing research illustrates that the question of who needs injection therapy is itself an area of active investigation (PMID 21623649). This page summarises what the literature and labeling describe and does not offer guidance on use.

Related reading

• B12 Injection: overview of the evidence

References

• The vitamin B12 absorption test, CobaSorb, identifies patients not requiring vitamin B12 injection therapy (Scandinavian Journal of Clinical and Laboratory Investigation, 2011)
• Combined Ultrasound-guided Perineural Vitamin B12 Injection and Pulsed Radiofrequency of C2 Dorsal Root Ganglion for Treatment of C2 Postherpetic Neuralgia: A Case Report (Journal of Medical Ultrasound, 2026)
• Vitamin B12 injection plus traditional Chinese medicine techniques for meralgia paresthetica: a randomized controlled trial (Frontiers in Medicine, 2025)
• A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer (The Oncologist, 2014)
• Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy (Chinese Journal of Oncology, 2015)
• Disrupted one-carbon metabolism in heifers negatively affects their health and physiology (Journal of Animal Science, 2024)